BR112013010507A2 - compostos e composições para o tratamento de câncer - Google Patents

compostos e composições para o tratamento de câncer

Info

Publication number
BR112013010507A2
BR112013010507A2 BR112013010507A BR112013010507A BR112013010507A2 BR 112013010507 A2 BR112013010507 A2 BR 112013010507A2 BR 112013010507 A BR112013010507 A BR 112013010507A BR 112013010507 A BR112013010507 A BR 112013010507A BR 112013010507 A2 BR112013010507 A2 BR 112013010507A2
Authority
BR
Brazil
Prior art keywords
formula
compounds
compositions
cancer treatment
treatment compounds
Prior art date
Application number
BR112013010507A
Other languages
English (en)
Portuguese (pt)
Inventor
Boulos Zacharie
Brigitte Grouix
Christopher Penney
Lilianne Geerts
Lyne Gagnon
Pierre Laurin
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of BR112013010507A2 publication Critical patent/BR112013010507A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32—Phenylacetic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/84—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/18—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/48—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/54—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/18—Saturated compounds containing keto groups
    • C07C62/20—Saturated compounds containing keto groups with a saturated six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112013010507A 2010-10-27 2011-10-26 compostos e composições para o tratamento de câncer BR112013010507A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40706910P 2010-10-27 2010-10-27
PCT/CA2011/001179 WO2012097427A1 (en) 2010-10-27 2011-10-26 Compounds and compositions for the treatment of cancer

Publications (1)

Publication Number Publication Date
BR112013010507A2 true BR112013010507A2 (pt) 2016-08-02

Family

ID=46515034

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013010507A BR112013010507A2 (pt) 2010-10-27 2011-10-26 compostos e composições para o tratamento de câncer

Country Status (24)

Country Link
US (2) US9114118B2 (enExample)
EP (2) EP2632452B1 (enExample)
JP (2) JP6007186B2 (enExample)
KR (2) KR101821646B1 (enExample)
CN (2) CN105997967B (enExample)
AU (2) AU2011356583C1 (enExample)
BR (1) BR112013010507A2 (enExample)
CA (1) CA2816093C (enExample)
CL (1) CL2013001152A1 (enExample)
DK (2) DK3443957T3 (enExample)
EA (2) EA035494B1 (enExample)
ES (2) ES2703257T3 (enExample)
IL (2) IL225599A (enExample)
MX (2) MX381345B (enExample)
MY (2) MY184343A (enExample)
NZ (1) NZ610851A (enExample)
PH (2) PH12013500766B1 (enExample)
PL (2) PL3443957T3 (enExample)
PT (2) PT3443957T (enExample)
SG (2) SG10201807622WA (enExample)
TR (1) TR201819987T4 (enExample)
TW (2) TWI620563B (enExample)
WO (1) WO2012097427A1 (enExample)
ZA (1) ZA201303035B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI620563B (zh) * 2010-10-27 2018-04-11 波麥堤克藥學Ｓｍｔ有限公司 用於治療癌症的化合物及組成物
TWI689489B (zh) 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
RU2560702C1 (ru) * 2014-06-05 2015-08-20 Общество с ограниченной ответственностью "Научно-производственный центр "Амфион" (ООО "НПЦ "Амфион") Фармацевтическая композиция для применения в онкологии
RU2709205C2 (ru) 2014-10-10 2019-12-17 Прометик Фарма Смт Лимитед Замещенные ароматические соединения и фармацевтические композиции для предотвращения и лечения остеопороза
CA2963358C (en) * 2014-10-10 2023-03-07 Prometic Biosciences Inc. Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
US10391073B2 (en) * 2014-11-12 2019-08-27 Prometic Pharma Smt Limited Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration
CN106267213A (zh) * 2015-05-27 2017-01-04 聊城市奥润生物医药科技有限公司 环二核苷酸cGAMP在治疗肿瘤联合用药中的应用
WO2019023388A1 (en) 2017-07-25 2019-01-31 Taris Biomedical Llc METHODS OF TREATING TUMOR METASTASIS
CA3081839A1 (en) 2017-11-08 2019-05-16 Taris Biomedical Llc Methods of treatment and maintenance therapy for bladder cancer using gemcitabine
JP2022510436A (ja) * 2018-12-05 2022-01-26 リミナル・バイオサイエンシーズ・リミテッド アルストレーム症候群の治療における２－（３－ペンチルフェニル）酢酸ナトリウムの使用
US11246945B2 (en) 2019-06-07 2022-02-15 National Defense Medical Center Cisplatin-loaded microbubbles, pharmaceutical composition for treatment of cancer, method for preparing pharmaceutical compositions and method for treating cancer
MX2022000570A (es) 2019-07-26 2022-03-11 Espervita Therapeutics Inc Acidos mono- y dicarboxilicos hidrocarbonados de cadena larga funcionalizados y su uso para la prevencion o el tratamiento de enfermedad.
US20240043372A1 (en) * 2020-10-06 2024-02-08 Pharmaceutique Ingenew Inc. Substituted aromatic compounds and pharmaceutical compositions thereof
KR20230152007A (ko) 2021-01-25 2023-11-02 에스퍼비타 테라퓨틱스, 인크. 작용화된 장쇄 카복실산, 및 질환의 치료를 위한 이의 용도
CN114436822B (zh) * 2022-01-12 2024-04-16 厦门稀土材料研究所 一枝蒿酮酸和生物碱复盐及其制备方法和用途
AU2024239546A1 (en) * 2023-03-22 2025-10-02 Uti Limited Partnership Hydroxyphenyl propanoate compounds for tumour immunotherapy, compositions and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268907A3 (en) 1986-11-19 1990-03-21 Carl Richard Thornfeldt Treatment of disease conditions relating to hyperactive organelles
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
ITMI20012434A1 (it) 2001-11-20 2003-05-20 Dompe Spa Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono
CN1169768C (zh) * 2002-04-26 2004-10-06 中国科学院上海有机化学研究所 （4－炔基）－芳香酮酸类化合物、合成方法及应用
CA2506897A1 (en) * 2002-12-27 2004-07-15 Tibotec Bvba Fluorogenic enzyme substrates and methods of preparation
WO2005010202A2 (en) * 2003-07-16 2005-02-03 Ligand Pharmacueticals Incorporated PHENYL ACETIC ACID DERIVATIVES AS HEPATOCYTE NUCLEAR FACTOR 4α (HNF-4α) MODULATOR COMPOUNDS
WO2005009104A2 (en) * 2003-07-16 2005-02-03 Ligand Pharmacueticals Incorporated Benzoic and phenyl acetic acid derivatives as hnf-4 modulators
US8198328B2 (en) * 2004-01-21 2012-06-12 New York University Treatment of cancer using benzoic acid derivatives
JP2010502586A (ja) 2006-09-01 2010-01-28 ピラマル・ライフ・サイエンシーズ・リミテッド コーヒー酸と誘導体の抗ガン用途
WO2008112368A2 (en) * 2007-02-08 2008-09-18 Emisphere Technologies, Inc. Phenylalkylcarboxylic acid delivery agents
WO2009055932A1 (en) 2007-11-02 2009-05-07 Prometic Biosciences Inc. Substituted phenylpropionic acids as stimulators of hematopoiesis and erythropoiesis
RU2519215C2 (ru) * 2007-11-02 2014-06-10 Прометик Байосайенсиз Инк. Жирные кислоты и глицериды со средней длиной цепи в качестве нефропротективных средств
WO2009076761A1 (en) * 2007-12-19 2009-06-25 Prometic Biosciences Inc. Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer
TWI485134B (zh) * 2009-05-04 2015-05-21 波麥堤克生化科學公司 取代的芳族化合物及其藥學用途
JP5844251B2 (ja) * 2009-05-04 2016-01-13 プロメティック・バイオサイエンシーズ・インコーポレイテッドＰｒｏＭｅｔｉｃ ＢｉｏＳｃｉｅｎｃｅｓ Ｉｎｃ． ３−ペンチルフェニル酢酸の塩およびその薬学的使用
TWI620563B (zh) * 2010-10-27 2018-04-11 波麥堤克藥學Ｓｍｔ有限公司 用於治療癌症的化合物及組成物

Also Published As

Publication number Publication date
MY184343A (en) 2021-04-01
EP2632452A4 (en) 2014-05-07
EP2632452B1 (en) 2018-09-26
US20150313856A1 (en) 2015-11-05
PT2632452T (pt) 2019-01-10
IL251083A0 (en) 2017-04-30
DK3443957T3 (da) 2020-12-21
AU2016201556A1 (en) 2016-04-14
AU2011356583C1 (en) 2016-03-17
US9114118B2 (en) 2015-08-25
IL225599A0 (en) 2013-06-27
TW201305097A (zh) 2013-02-01
KR101943280B1 (ko) 2019-01-28
MY162420A (en) 2017-06-15
PT3443957T (pt) 2020-12-18
NZ610851A (en) 2015-05-29
EP2632452A1 (en) 2013-09-04
US9439882B2 (en) 2016-09-13
TWI620563B (zh) 2018-04-11
PH12013500766A1 (en) 2013-06-24
JP2016188247A (ja) 2016-11-04
JP2013544799A (ja) 2013-12-19
DK2632452T3 (en) 2019-01-21
WO2012097427A1 (en) 2012-07-26
SG10201807622WA (en) 2018-10-30
TW201717928A (zh) 2017-06-01
IL251083B (en) 2018-07-31
CA2816093A1 (en) 2012-07-26
US20130217645A1 (en) 2013-08-22
EA035494B1 (ru) 2020-06-25
TWI578983B (zh) 2017-04-21
PL2632452T3 (pl) 2019-03-29
KR101821646B1 (ko) 2018-01-25
EP3443957B1 (en) 2020-11-25
TR201819987T4 (tr) 2019-01-21
PH12016502324B1 (en) 2023-10-11
JP6371344B2 (ja) 2018-08-08
KR20130132448A (ko) 2013-12-04
CN103347509A (zh) 2013-10-09
CL2013001152A1 (es) 2014-01-10
AU2016201556B2 (en) 2017-09-14
PH12013500766B1 (en) 2017-09-29
MX365807B (es) 2019-06-14
CN103347509B (zh) 2016-06-08
JP6007186B2 (ja) 2016-10-12
CN105997967B (zh) 2019-08-23
IL225599A (en) 2017-05-29
MX2019007010A (es) 2019-09-06
EP3443957A1 (en) 2019-02-20
SG189538A1 (en) 2013-06-28
PH12016502324A1 (en) 2019-07-15
MX2013004832A (es) 2013-05-22
ES2703257T3 (es) 2019-03-07
MX381345B (es) 2025-03-12
KR20180011332A (ko) 2018-01-31
ES2837599T3 (es) 2021-06-30
CN105997967A (zh) 2016-10-12
ZA201303035B (en) 2014-06-25
HK1189836A1 (zh) 2014-06-20
PL3443957T3 (pl) 2021-05-04
EA030038B1 (ru) 2018-06-29
EA201791585A1 (ru) 2018-05-31
AU2011356583B2 (en) 2015-12-24
CA2816093C (en) 2020-12-01
AU2011356583A1 (en) 2013-05-09
EA201370103A1 (ru) 2013-12-30

Similar Documents

Publication Publication Date Title
BR112013010507A2 (pt) compostos e composições para o tratamento de câncer
CL2011000504A1 (es) Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer.
BR112012030699A2 (pt) métodos para tratar câncer de bexiga
BRPI0916286B8 (pt) amidofenóxi-indazóis úteis como inibidores de c-met, seus usos, e composição farmacêutica
UY31215A1 (es) Compuestos de morfolino pirimidina, procesos para su preparacion, composiciones farmacéuticas conteniéndolos y su uso en terapia.
UA110943C2 (uk) N-ацилсульфонамідні промотори апоптозу
BR112012024349A2 (pt) métodos de tratamento de carcinoma hepatocelular
BR112015014585A2 (pt) composto, composição farmacêutica, e, método de tratamento de um ser humano
BR112015001502A2 (pt) derivados de tipo azaindazol ou diazaindazol para tratamento de dor
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
PH12012500804A1 (en) Chromenone derivatives with anti-tumour activity
CR20120528A (es) Métodos para tratar el cáncer
CU20140068A7 (es) Triazolopiridinas sustituidas
CO6670525A2 (es) Quelatos de oligonucleótidos
MX2013012289A (es) Triazolopiridinas.
CO6650348A2 (es) Triazolopiridinas sustituidas
CO6341625A2 (es) Derivados de indol como agentes anticáncer
MX381967B (es) Compuestos de 2,3-dihidrobenzofuran-5-ilo como inhibidores de quinasas dyrk.
CL2010000804A1 (es) Compuestos derivados de 3-(1 h-pirrol-2-il-metil)-1 ,3-dihidro-2h-indol-2-ona; procedimientos de preparación de dichos compuestos; composición farmacéutica y combinación farmacéutica que los comprende; y su uso para el tratamiento de cáncer.
NZ595615A (en) Combination therapy against cancer utilising 3-beta-cholestanyl-3-O-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-beta-D-galactopyranoside and is derivatives
BR112014009288A2 (pt) formas sólidas de 1,l-dioxo-4-tiomorfolinil)-[6-[[3(4-fluorofenil)-5-metil-4-isoxazolil]metóxi]-3-piridinil]-metanona
AR077483A1 (es) Sal de citrato del 9e-15-(2-pirrolidin -1-il-etoxi)-7,12,25-trioxa-19-21,24-triaza-tetraciclo (18-3.1.1(2,5).1(14,18) hexacosa-1 (24),2,4,9,14,16,18 (26),20,22- nonaeno
ECSP13012904A (es) Compuestos de complejos de fe(iii) para el tratamiento y profilaxis de síntomas de deficiencia de hierro y anemias por deficiencia de hierro
UY32360A (es) Compuestos de etanamina y métodos de utilización de los mismos 545
BR112012006073A2 (pt) composições e métodos para tratar espasticidade.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: PROMETIC PHARMA SMT LIMITED (CA)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements